Full-Time
Data Scientist
Posted on 9/22/2025
UntilLabs
51-200 employees
Advances reversible organ cryopreservation technology
Compensation Overview
$120k - $160k/yr
California, USA
In Person
 Data & Analytics (2) |
|---|
| , |
- Degree in Computer Science, Data Science, Applied Mathematics, Statistics, or in a scientific field coupled with substantial data science experience.
- Demonstrated ability to write modular, maintainable, and reproducible code in Python.
- Proficiency with the Python data science stack, including Polars or Pandas, NumPy, SciPy, Matplotlib, and Plotly.
- Strong foundation in probability, statistics, and data modeling.
- Experience designing schemas and working with structured datasets, with proficiency in SQL for querying and analysis.
- Ability to communicate complex findings clearly to interdisciplinary teams.
- Ability to think from first principles and tackle complex, cross-disciplinary problems with other scientists and engineers.
- Own the full lifecycle of experimental data from generation in the lab to processing, analysis, and visualization.
- Build the infrastructure and pipelines that move data reliably from instruments to insight,
- Designing reproducible workflows and tools that help the team explore results quickly and clearly.
- Work closely with scientists and engineers, setting a high bar for data integrity and usability across the team.
- PhD, Master’s degree, or 3+ years of relevant professional experience.
- Experience with machine learning or predictive modeling, or working with large datasets.
- Experience or exposure to a scientific field such as biology, chemistry, or physics.
UntilLabs develops reversible cryopreservation technology to extend the viability of human organs for transplantation. The goal is to keep organs alive at cryogenic temperatures long enough to improve organ matching and reduce waste from time limits, potentially weeks or months of preserved time. The approach uses cooling to very low temperatures (below -130°C) with cryoprotectants to prevent ice damage, followed by advanced warming methods to revive the organs without harm. While cryopreservation has worked for cells and simple tissues, UntilLabs works on scaling this to whole organs, tackling challenges like ice formation and nutrient/waste management in large tissues. In the long term, the company envisions whole-body reversible cryopreservation as a bridge to future medical cures.
Company Size
51-200
Company Stage
N/A
Total Funding
N/A
Headquarters
San Francisco, California
Founded
2024
Simplify's Take
What believers are saying
- Raised $58M Series A in September 2025 from Founders Fund, Lux Capital, Field Ventures.
- Enables organ banking, better matching, reduces waitlist deaths from time constraints.
- Foundational for whole-body preservation, backed by over $100M funding.
What critics are saying
- FDA lacks approval framework, delaying commercialization 3-5 years.
- Normothermic systems from OrganOx, Transmedics capture market pre-approval.
- Cryoprotectant toxicity triggers rejection, forces redesign in 24-36 months.
What makes UntilLabs unique
- Until Labs develops reversible cryopreservation for organs using vitrification without ice formation.
- Engineers five dimensions: perfusion, cryoprotectants, cooling, rewarming, and post-thaw assays.
- Progressed from neural slices to preclinical kidneys, hearts, lungs, livers.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Flexible Work Hours
Paid Holidays
401(k) Retirement Plan
Health Savings Account/Flexible Spending Account
Commuter Benefits
Professional Development Budget
Company News
Until Labs announced a $58 million Series A funding round led by Founders Fund, with Lux Capital and Field Ventures participating. The company focuses on developing technology for organ-scale reversible cryopreservation, allowing donor organs to be preserved indefinitely and rewarmed for transplant. The funding will help expand their multidisciplinary team to enhance their cryopreservation methods, aiming to improve organ matching and reduce organ waste.
Fenwick represents Until Labs in $58M Series A funding.